US Amjevita Sales Slide By Almost Two-Thirds

Amgen’s Humira Biosimilar Turnover Slides In US Ahead Of Fresh Wave Of Launches

Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira.

Amgen logo syringe vials
Amgen saw US sales of its Humira biosimilar drop by nearly two-thirds in Q2 • Source: Shutterstock

Amgen was the frontrunner among US Humira (adalimumab) biosimilar competitors in 2023, launching its Amjevita (adalimumab-atto) biosimilar at the end of January and gaining a five-month head start on its numerous rivals.

However, while this early launch delivered $51m in US sales during the two-month period that it was available in the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.